Boehringer Ingelheim (BI) reports that Allan Hillgrove, member of the company’s Board of Managing Directors responsible for the Human Pharma and the Biopharma business, will retire at the end of this year and will be succeeded by Dr. Carine Brouillon, currently head of Therapeutic Areas for Prescription Medicines at BI, effective January 1, 2020.

Dr. Brouillon joined BI in 2018 from Johnson & Johnson. She has an academic background in natural science and economics as well as broad international expertise in product, marketing, and commercial strategies.

Allan Hillgrove joined BI in 1982 in Australia as a sales representative in Animal Health. Throughout his career, he held numerous Human Pharma management positions in Australia and corporate, including Head of Corporate Department Respiratory Marketing. In 2013, the shareholders appointed him to the Board of Managing Directors with the leadership of the Human Pharma Business, adding responsibility for the Biopharma Business in 2018.

In another move, at the end of 2019, Dr. Joachim Hasenmaier, Member of the Board of Managing Directors, will also retire and step down from the board and his responsibility for the Animal Health business. Dr. Joachim Hasenmaier joined BI in 2011 as Head of the Animal Health Division. He led the business into a period of growth, which included acquisitions such as parts of Fort Dodge, an animal health company, in 2009. In 2012 he was appointed as Member of the Board of Managing Directors with responsibility for the two businesses, Animal Health as well as Consumer Health Care.

The BI shareholders have decided to appoint Jean Scheftsik de Szolnok as Member of the Board of Managing Directors and new Head of the Animal Health Business Unit, effective January 1, 2020. He joined BI in 1987. Since September 2017, he has been the Country Managing Director of France. In this role, he managed the Merial integration and further development of the Lyon site as a research, development and production site for the animal health business. Before that, he held various leadership positions in Germany as well as in Canada, Belgium and France.

In addition, Dr. Andreas Neumann has decided to step down from the Board of Managing Directors at the end of September 2019 and will leave the corporation after more than eight years. He held the position of General Counsel from 2011 until 2015. During this time, the global compliance concept and a corresponding organization was established. Dr. Andreas Neumann was then appointed to the Board of Managing Directors with responsibility for Human Resources.

Source: Boehringer Ingelheim